Royal Bank of Canada Trims Holdings in Certara, Inc. $CERT

Royal Bank of Canada lowered its stake in shares of Certara, Inc. (NASDAQ:CERT) by 19.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,009,089 shares of the company’s stock after selling 245,200 shares during the period. Royal Bank of Canada owned 0.65% of Certara worth $5,752,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Granite Investment Partners LLC purchased a new stake in Certara during the first quarter valued at about $2,130,000. UBS Group AG lifted its stake in shares of Certara by 50.7% during the 4th quarter. UBS Group AG now owns 2,489,603 shares of the company’s stock valued at $21,933,000 after buying an additional 837,648 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Certara by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after buying an additional 175,024 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Certara by 412.5% in the 1st quarter. Quantinno Capital Management LP now owns 988,990 shares of the company’s stock worth $5,637,000 after buying an additional 796,007 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Certara in the 1st quarter worth approximately $1,980,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Stock Performance

NASDAQ:CERT opened at $8.01 on Thursday. The stock has a market cap of $1.22 billion, a P/E ratio of -17.80 and a beta of 1.44. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The business’s 50-day moving average price is $6.70 and its two-hundred day moving average price is $6.50. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $13.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.07 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the topic of several recent research reports. Craig Hallum dropped their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th. Stephens dropped their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Morgan Stanley reduced their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. BMO Capital Markets lowered their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings raised shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.28.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.